Top Markets
Coin of the day
GH Research PLC GH Research PLC

GH Research PLC

GHRS
Pozycja w akcjach #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Cena akcji
$28.53
Kapitalizacja rynkowa
$1.96B
Zmiana (1 dzień)
-1.65%
Zmiana (1 rok)
109.32%
Kraj
IE
Handel GH Research PLC (GHRS)

Kategoria

Historia ceny akcji dla GH Research PLC (GHRS)
Najwyższa cena zamknięcia: $29.28 dnia 2026-08-01

Najniższa cena zamknięcia: $20.43 dnia 2021-06-01
Historia cen akcji firmy GH Research PLC od 2021 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) 34.51%
2025 71.80%
2024 35.29%
2023 -44.18%
2022 -56.09%
2021 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$548.36 40.94%
US
$1.06K 49.46%
NL
$122.63 -12.65%
AU
$140.81 461.00%
US
$765.25 7.19%
CH